HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Naito, T. Articles by Kozbor, D. Search for Related Content PubMed PubMed Citation Articles by Naito, T. Articles by Kozbor, D. Agricola Articles by Naito, T. Articles by Kozbor, D.

Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization

Toshio Naito^1,

¹ Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA 19122, USA
² Institute of Immunotherapy and Research for Cancer, Kinki University, Osaka 589-8511, Japan
³ Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Correspondence
Toshio Naito
naito{at}med.juntendo.ac.jp

Development of a safe and effective vaccine for induction of mucosal immunity to the human immunodeficiency virus (HIV) envelope glycoprotein (Env, gp160) represents the best hope for containing the spread of an HIV epidemic worldwide. The highly attenuated modified vaccinia virus Ankara (MVA) is a laboratory virus well suited as a safe vaccine vector. However, the presence of pre-existing immunity to Vaccinia virus in the adult population represents a hindrance that limits the application of the MVA vector for inducing immunity to HIV antigens. Here, cationic liposomes were covalently attached to the surface of recombinant MVA expressing the HIV-1 strain IIIB Env glycoprotein and -galactosidase (MVA_IIIB/-gal) using tresylmonomethoxypolyethylene glycol (TMPEG) grafted into a lipid membrane without compromising viral infectivity in vitro and in vivo. The orally administered MVA_IIIB/-gal–TMPEG/liposome complexes were capable of delivering the transgenes to mucosal tissues in mice with pre-existing poxvirus immunity based on -galactosidase gene expression in intestinal tissues measured 18 h after infection. Importantly, the MVA_IIIB/-gal–TMPEG/liposome complexes enhanced Env-specific cellular and humoral immune responses in the mucosal and systemic tissues after repeated oral immunization of BALB/c mice. This approach may prove useful for induction of protective immunity against infectious diseases and cancer in populations with pre-existing immunity to vaccinia from smallpox vaccination.

Present address: Department of General Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan.

This article has been cited by other articles:

				M. Corbett, W. M. Bogers, J. L. Heeney, S. Gerber, C. Genin, A. Didierlaurent, H. Oostermeijer, R. Dubbes, G. Braskamp, S. Lerondel, et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic PNAS, February 12, 2008; 105(6): 2046 - 2051. [Abstract] [Full Text] [PDF]